Vedolizumab as induction and maintenance therapy for ulcerative colitis.

By B. Feagan, P. Rutgeerts, Bruce E. Sands, S. Hanauer, J. Colombel, W. Sandborn, G. Van Assche, J. Axler, Hyo-Jong Kim, S. Danese and 6 more. New England Journal of Medicine, 2013

2,298 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. (2017, neutral): “Gastroenterology 2012; 142(2): 257-65.”
The Human Gut Microbiome – A Potential Controller of Wellness and Disease (2018, background): “Anti-inflammation therapies such as antibodies targeting proinflammatory cytokines (anti-TNF-alpha, anti-IL12, antiIL23) and employing α4β7-integrin antagonist to inhibit trafficking of T-lymphocytes to gut tissue (Feagan et al., 2013; Christensen et al., 2015).”
ACG Clinical Guideline: Ulcerative Colitis in Adults (2019, methodology): “In the GEMINI 1 induction trial, 374 patients were randomized in a comparison cohort to receive vedolizumab or placebo at weeks 0 and 2, whereas 521 patients were enrolled in the open-label vedolizumab cohort (135).”
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. (2015, result): “The benefit was relatively modest, but our end point for treatment success was more stringent than most trials in UC(23) and remission rates seen with FMT were consistent with a similar end point for a novel biologic therapy.(7) The secondary end points were not met in this trial.”